Joachim M Baehring, MD

Associate Professor of Medicine (Medical Oncology), of Neurology and of Neurosurgery; Clinical Program Leader, Brain Tumor Program, Smilow Cancer Hospital

Clinical Interests

  • Brain Neoplasms

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Brain Tumor Center | Hematology Program

Neurology: Brain Tumors and Neuro-Oncology | Stroke Center, Yale-New Haven

Neurosurgery

Yale Medical Group

Board Certifications

  • Neurology AB of Psychiatry & Neurology (2001)

Clinical Trials

Conditions Study Title
Unknown Sites Study of Immune System in Patients with Cancer and Blood Disorders
Brain and Nervous System A Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients with Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II)
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Neurology Blood Draw Protocol
Brain and Nervous System 13C magnetic resonance spectroscopy (MRS) methods for quantitative in vivo measurement of brain tumor metabolism
Bladder, Brain and Nervous System, Breast - Female, Colon, Lung, Other Urinary Randomized Controlled Study of Neurocognitive Outcomes in Patients with Five or More Brain Metastases Treated with Radiosurgery or Whole-Brain Radiotherapy - CC121010/NAGKC12-01
Brain and Nervous System A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination with Ipilimumab Across Different Lines of Glioblastoma
Brain and Nervous System TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride with Hypofractionated Re-Irradiation Therapy in Treating Patients with Recurrent Glioblastoma Multiforme (GBM)
Brain and Nervous System A Phase II Trial of High-Dose Rituximab Combined with Temozolomide as Treatment for Patients with Primary CNS Lymphoma

Edit this profile

Contact Info

Joachim M Baehring, MD
Patient Care Locations
Yale Brain Tumor ProgramSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 8th Floor Multispecialty Care Center

New Haven, CT 06511
77 Lafayette Place
Greenwich, CT 06830
Mailing Address
Neuro-Oncology 15 York Street LLCI 920
PO Box 208082

New Haven, CT 06520-8082